(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/194123 A1

(51) International Patent Classification:
C07K 16/46 (2006.01) *C12N 15/62* (2006.01)
A61K 47/68 (2017.01) *C12N 15/85* (2006.01)
C07K 16/30 (2006.01) *G01N 33/574* (2006.01)
C07K 16/32 (2006.01) *A61K 40/33* (2025.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2025/020064

(22) International Filing Date:
14 March 2025 (14.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/566,201 15 March 2024 (15.03.2024) US
63/724,854 25 November 2024 (25.11.2024) US

(71) Applicant: **AARVIK THERAPEUTICS, INC.** [US/US]; 31363 Medallion Drive, Hayward, California 94544 (US).

(72) Inventors: **JUNUTULA, Jagath Reddy**; 31363 Medallion Drive, Hayward, California 94544 (US). **BLAZER, Levi L.**; 31363 Medallion Drive, Hayward, California 94544 (US). **ADAMS, Jarrett**; 31363 Medallion Drive, Hayward, California 94544 (US). **BHAKTA, Sunil**; 31363 Medallion Drive, Hayward, California 94544 (US). **SIDHU, Sachdev Singh**; 31363 Medallion Drive, Hayward, California 94544 (US).

(74) Agent: **WHITTLE, James** et al.; Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: MUC16/NAPI-2B ANTIBODIES AND METHODS OF USE

(57) **Abstract:** Provided herein are multivalent, bi-specific antibodies that specifically bind Muc16 and NaPi-2b. In certain embodiments, the antibodies are bivalent, trivalent or tetravalent. Certain tetravalent antibodies comprise two paratopes that specifically bind Muc16, and two paratopes that specifically bind NaPi-2b. Embodiments of tetravalent antibodies described herein include a Diabody-Fc-Fab format (MUTTA^{TM} 2) and a Fab-Diabody-Fc format (MUTTA^{TM} 4). Also provided are immunoconjugates, which may be antibody-drug conjugates. Further provided are methods of using these antibodies for killing or detecting malignant cells and for treating diseases, including cancer.

WO 2025/194123 A1